ChipCare Corporation, a Toronto, Canada-based company commercializing a handheld, blood-testing platform for HIV and other infectious and non-communicable diseases, closed a $5.045m Series A financing.
The round was led by Puffin Partners, with participation from existing investors MaRS Innovation and Maple Leaf Angels, and new investors the Winfield Venture Group, Epic Capital, and additional Canadian and U.S. angel investors.
The company intends to use the funds to bring its product to market while further developing next generation products.
Led by James Fraser, CEO, ChipCare is a University of Toronto startup producing life-saving diagnostics for infectious and non-communicable diseases in remote health settings with a mobile blood-testing platform. The company’s first HIV-related test, targeted at linking people with HIV to appropriate treatments, is scheduled to go to market in late 2016.